Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eni SpA (E) vs Eli Lilly And Co (LLY) Price & Performance

Eni SpATrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Eni SpA vs Eli Lilly And Co — how do they compare? Eni SpA trades at $48.37 (market cap $70.34B), while Eli Lilly And Co trades at $1,180 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 14.6× Eni SpA's market cap, and Eni SpA pays the higher dividend (4.99%). Which is the better fit depends on your goals.

ELLY
Market Cap
$70.34B$1.03T
Sector
EnergyHealth
52-Week High
$57.61$1.24K
52-Week Low
$32.93$625.65
Enterprise Value
$89.25B$1.07T
Dividend Yield
4.99%0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eni SpA

Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.

The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eni SpA

Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude

Read more on E

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY